Results indicated that most GSC lines with high MGMT activity (≥200 fmol/mg) showed low sensitivity to TMZ, with IC50s >300 μM, a value which is well above the peak plasma concentration reached in cancer patients (20–96 μM at a TMZ dose of 200 mg/m2) [28]. This evidence concerns the gene MGMT and cancer.